このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

梨状筋症候群患者における坐骨神経の超音波検査による評価 (Sciatica)

2026年11月6日 更新者:Busra Sezer Kıral、Istanbul University - Cerrahpasa

Piriformis syndrome (PS) is defined as a neuropathy of entrapment resulting from compression and irritation of the sciatic nerve at the level of the piriformis muscle (PM) at the pelvic outlet, causing sciatica radiating to the leg. The neuropathic component of PS is the compression of the sciatic nerve in or around the PM, while the primary cause of the somatic component is myofascial pain of the PM. PS accounts for 6-8% of all hip and sciatic pain cases. It is more common in middle-aged patients, and the most common etiological cause is trauma. There are various methods for the diagnosis of Piriformis Syndrome. Clinically, tenderness on palpation of the PM is the most common symptom. The FAIR test (passive flexion adduction and internal rotation of the hip), the Freiberg test (forceful internal rotation of the thigh in the supine position), the Pace test (abduction of the leg against resistance while sitting) and the Beatty maneuver (active abduction of the thigh on the affected side in the lateral decubitus position) are maneuvers that help in diagnosis. It is known that there is a delay in proximal nerve conduction (H-reflex) on the pathological side compared to the healthy side in the FAIR maneuver on EMG in PS, and it is not a sufficient test for diagnosis alone. Some studies have reported increased piriformis thickness on the pathological side in MRI. None of these clinical and imaging methods are sufficient for diagnosis alone, and today ultrasonography (US) has become one of the most important imaging methods for musculoskeletal clinicians in the diagnosis of PS. Imaging with US and the diagnostic injection test applied to the piriformis muscle with US guidance are quite important for diagnosis. There are a number of studies in the literature evaluating PM with US. These studies have shown that the piriformis muscle thickness and echogenicity increase on the pathological side. However, there is a lack of studies in the literature focusing on the evaluation of the sciatic nerve with US in patients with PS. Our aim in this study is to compare the thickness of the PM and the sciatic nerve by measuring US on both the pathological and painless sides in patients with unilateral hip pain who were diagnosed with PS clinically, to record the variations present in the sciatic nerve, and to determine whether the myofascial pain or the neuropathic component is dominant in the disease.

調査の概要

状態

完了

介入・治療

詳細な説明

The sciatic nerve is the largest nerve in the body and is formed by the ventral roots of the lumbosacral plexus (L4-S3), passes through the foramen ischiadicum majus under the piriformis muscle (PM) and enters the gluteal region. It is controversial whether anatomical variations in the sciatic nerve and PM predispose to the development of Piriformis syndrome (PS). The sciatic nerve passes under the PM as a single branch in almost 90% of cases. However, there are some variations where it passes above and through the muscle or divides into tibial and peroneal branches, with one branch passing under the piriformis. There are a number of studies in the literature evaluating the PM with US. These studies have shown that the PM thickness and echogenicity increase on the pathological side. In addition, it has been mentioned that the sciatic nerve has a coarse and blurry image in patients complaining of sciatic pain. In one study, cross-sectional area measurement was performed instead of PM thickness measurement. However, this was criticized in later studies, and it was stated that it was difficult to calculate muscle volume exactly with two-dimensional US due to the irregular shape of the PM, which is anatomically pear-shaped, and that thickness measurement would provide more accurate results instead of cross-sectional area. In the first study in the literature focusing on the sciatic nerve in PS and the neuropathic pain it causes, it was found that the sciatic nerve was significantly enlarged (75%) on the symptomatic side and had decreased echogenicity in some patients when compared to healthy volunteers.

研究の種類

観察的

入学 (実際)

35

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~70年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Patients aged between 18 and 70 years with unilateral hip and/or leg pain, positive FAIR (flexion, adduction, internal rotation) test, and tenderness to palpation in the PM will be included in our study.

説明

Inclusion Criteria:

  • Patients aged between 18 and 70 years with unilateral hip and/or leg pain
  • Positive FAIR (flexion, adduction, internal rotation) test
  • Tenderness to palpation in the Piriformis muscle

Exclusion Criteria:

  • Patients with a history of previous surgery involving the lumbar and/or hip region
  • A history of malignancy or infection in the pelvic region
  • Body mass index (BMI) Greater than 30 kg/m2
  • Psychiatric diseases
  • Vascular disease
  • Uncontrolled diabetes, hypertension or heart failure,
  • Disc pathologies that may cause radiculopathy
  • History of rheumatic disease.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_ONLY
  • 時間の展望:CROSS_SECTIONAL

コホートと介入

グループ/コホート
介入・治療
Piriformis Syndrome Patients (n=20)

The ultrasound probe will be placed parallel to the body of the piriformis muscle on an imaginary line drawn from the sacrum to the greater trochanter of the femur. This area is also the sensitive area of the patients during the examination with pressure, and when the US probe is in this position, the subcutaneous fat tissue, gluteus maximus muscle, piriformis muscle, and the upper and lower borders of the sciatic nerve will be displayed in order from superficial to deep. First, the maximum thickness of the piriformis muscle body will be measured, then the thickness of the sciatic nerve will be measured, and the same measurements will be applied to the patient's asymptomatic hip, and the measurements will be recorded.

Healthy Controls (n=15)

The ultrasound probe will be placed parallel to the body of the piriformis muscle on an imaginary line drawn from the sacrum to the greater trochanter of the femur. This area is also the sensitive area of the patients during the examination with pressure, and when the US probe is in this position, the subcutaneous fat tissue, gluteus maximus muscle, piriformis muscle, and the upper and lower borders of the sciatic nerve will be displayed in order from superficial to deep. First, the maximum thickness of the piriformis muscle body will be measured, then the thickness of the sciatic nerve will be measured, and the same measurements will be applied to the patient's asymptomatic hip, and the measurements will be recorded.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Tenderness in the piriformis muscle by palpation, 0-10 NRS
時間枠:Day 1; single study visit

Tenderness in the piriformis muscle will be assessed by palpation using the numerical scale (NRS). The numerical scale is a pain score and is evaluated between 0 and 10.

Day 1; single study visit
Sciatic nerve thickness (measurement with US)
時間枠:Day 1; single study visit

Sciatic nerve thickness will be measured with ultrasound on the symptomatic and asymptomatic sides in the same patient.

Day 1; single study visit
Piriformis muscle thickness (measurement with US)
時間枠:Day 1; single study visit

Piriformis muscle thickness will be measured with ultrasound on the symptomatic and asymptomatic sides in the same patient.

Day 1; single study visit

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Selim Sezikli、Istanbul Physical Medicine Rehabilitation Training and Research Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年12月1日

一次修了 (実際)

2025年4月1日

研究の完了 (実際)

2025年4月1日

試験登録日

最初に提出

2025年1月7日

QC基準を満たした最初の提出物

2025年1月14日

最初の投稿 (実際)

2025年1月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する